Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
Studies have shown that patients with ESRD on hemodialysis have high levels of inflammatory
markers which may contribute to the high rates of cardiovascular disease and mortality seen
in these patients. Vitamin D use in dialysis patients has been shown to have a survival
benefit, with paricalcitol at advantage over calcitriol. Since there is some evidence for
involvement of the vitamin D receptor in inflammation, this study is designed to look for an
effect of paricalcitol on markers of inflammation in hemodialysis patients.